Searched for
PHARMEASY OPERATING REVENUE
FirstCry, Slice’s FY26 numbers; Nilekani’s Fundamentum eyes deeptech pushFirstCry parent cut its losses in the March quarter on tightened costs. This and more in today's ETtech Top 5.- PharmEasy to formally discuss IPO plans with its board in second trySources told ET that online pharmacy startup PharmEasy could hit the bourses this year, two years after its previous attempt. The company w...
- PharmEasy halves loss to Rs 2,533 crore in FY24, revenue dips 15%Mumbai-based PharmEasy, operated by API Holdings Limited, reported a net loss of Rs 2,533 crore, an improvement from the Rs 5,212 crore los...
- Tata 1mg’s FY24 operating revenue up 21% to Rs 1,968 croreTata 1mg’s net loss plummeted to Rs 313 crore from Rs 1,255 crore in the previous financial year. Over 80% of the company’s operating reven...
- PharmEasy’s FY23 operating revenue up 16% to Rs 6,644 crore; net loss widens 30%PharmEasy’s parent firm API Holdings cut down its advertising and promotional expenses to Rs 235 crore, less than half of what it incurred ...
- 1mg overtakes PharmEasy in market share in top order changeTata 1mg had a 31% market share in September 2023 against 19% in October 2022 while PharmEasy slipped to 15% from about 33% during the same...
- Exclusive: PharmEasy plans Rs 2,400-crore rights issue at 90% discount to repay loanMumbai-based epharmacy platform PharmEasy is likely to be valued at $500-600 million compared to the $5.6 billion valuation in 2021
- Global asset manager Janus Henderson cuts PharmEasy valuation further to $2.7 billionAs of March 31, 2023, funds managed by Janus Henderson valued their stake in the startup at $2.7 billion – less than half of the $5.6 billi...
- PharmEasy fails to raise Rs 1,000 crore equity, breaches covenant on Goldman Sachs loanPharmEasy was supposed to raise equity of around Rs 1,000 crore, or about $120 million, linked to its burn rate velocity. It has failed to ...
- PharmEasy logs first ebitda profit of Rs 14 crore in April, restarts funding talksThe epharmacy held discussions with CDPQ, ADQ; convertible notes are also being discussed amid valuation corrections and markdowns.
- US investor Janus Henderson cuts PharmEasy valuation by half to $2.8 billionThe global investor, which picked a stake in PharmEasy in September 2021, has reduced the valuation of its holding in the firm by half, whi...
- Exclusive | Not selling Thyrocare, will cut cash burn: PharmEasy founders to boardPharmEasy’s parent API Holdings has also delayed internal plans for a potential initial public offering (IPO) to 2025, the people privy to ...
- PharmEasy delays IPO, targets Ebitda breakeven by next yearThe Mumbai-based firm is also stitching up a private financing round through a rights issue where company founders are expected to invest p...
- Watch out for these factors in Thyrocare as closely as you would watch any symptoms!Through strategic acquisitions in the healthcare space, the company seems to be aiming to create “a holistic healthcare ecosystem”. From th...
- Buy Thyrocare Technologies, target price Rs 1310: HDFC SecuritiesThyrocare Technologies Ltd., incorporated in the year 2000, is a Mid Cap company (having a market cap of Rs 5758.02 Crore) operating in Hos...
- PharmEasy parent API Holdings strengthens board ahead of IPOAPI Holdings — the parent company of PharmEasy — has appointed five independent directors to its board. India's biggest online pharmacy is ...
- Thyrocare set for fast track with PharmEasyThyrocare is primarily a B2B diagnostic services provider. With PharmEasy’s presence, it will no longer be seen as a conventional diagnosti...
- PharmEasy valued at $1.8 billion as B Capital buys stake for $20 millionE-pharmacy conducts $3 million Esop buyback; Tiger Global also putting primary capital in Mumbai-based startup.
- B Capital, Tiger Global eye PharmEasy stakeThe total size of the transaction could be about $40 million and may value the company at about $1.8 billion, up from the current $1.5 bill...
- Medlife revenue up 165% to Rs 363 cr, losses surge tooIn August, Medlife appointed former Myntra CEO Ananth Narayanan as CEO and cofounder, with a mandate to head day-to-day operations, raise f...
Load More
